1. Faroughi F, Fathnezhad-Kazemi A, Sarbakhsh P. Factors affecting quality of life in women with breast cancer: a path analysis. BMC Womens Health 2023;23:578. [ DOI:10.1186/s12905-023-02755-9] 2. Alzahrani SM, Al Doghaither HA, Al-Ghafari AB. General insight into cancer: An overview of colorectal cancer (Review). Mol Clin Oncol 2021;15:271. [ DOI:10.3892/mco.2021.2433] 3. Faulkner S, Jobling P, March B, Jiang CC, Hondermarck H. Tumor Neurobiology and the War of Nerves in Cancer. Cancer Discov 2019;9:702-710. [ DOI:10.1158/2159-8290.CD-18-1398] 4. Ceyhan GO, Liebl F, Maak M, Schuster T, Becker K, Langer R, et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010;252:797-804. [ DOI:10.1097/SLA.0b013e3181fcab8d] 5. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012;18:1201-6. [ DOI:10.1158/1078-0432.CCR-11-0641] 6. Sharkawi FZ, Shemy HA, Khaled H. Anticancer activity of some commercial antihypertensive drugs by Neutral Red assay. Life Sci J 2013;10:609-613. 7. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell cycle 2007;6:430-3. DOI: 10.4161/cc.6.4.3829 [ DOI:10.4161/cc.6.4.3829] 8. Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol 2012;4:113-25. [ DOI:10.1177/1758834012439738] 9. Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009;22:825-30. [ DOI:10.3892/or_00000505] 10. Pimentel MA, Chai MG, Le CP, Cole SW, Sloan EK, Eds. Sympathetic nervous system regulation of metastasis. Madame Curie Bioscience Database: Landes Bioscience; 2013. 11. Caparica R, Bruzzone M, Agostinetto E, De Angelis C, Fêde Â, Ceppi M, de Azambuja E. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open 2021;6:100066. [ DOI:10.1016/j.esmoop.2021.100066] 12. Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H. Propranolol. Profiles Drug Subst Excip Relat Methodol 2017;42:287-338. [ DOI:10.1016/bs.podrm.2017.02.006] 13. Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, Requena T, Swiatecka D, Wichers H, Eds. The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet]. Cham (CH): Springer; 2015. [ DOI:10.1007/978-3-319-16104-4] 14. Wang F, Liu H, Wang F, Xu R, Wang P, Tang F, et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep 2018;17:5213-5221. [ DOI:10.3892/mmr.2018.8476] 15. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9. 16. Hu Q, Liao P, Li W, Hu J, Chen C, Zhang Y. Clinical use of propranolol reduces biomarkers of proliferation in gastric cancer. Front Oncol 2021;11:613-628. [ DOI:10.3389/fonc.2021.628613] 17. Brohée L, Demine S, Willems J, Arnould T, Colige AC, Deroanne CF. Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget 2011;1126:1-15. 18. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 2010;28:4094-4098. [ DOI:10.1200/JCO.2009.26.9357] 19. Acevedo Santiago A, Cruz Robles M, Monteiro AN, Armaiz Pena GN. Characterizing the Contribution of Adrenergic Signaling to Olaparib Resistance in Ovarian Cancer Cells. The FASEB J 2022;S1:36-41. [ DOI:10.1096/fasebj.2022.36.S1.R2127] 20. Giampieri, R. Cantini, L. Giglio, E. Bittoni, A. Lanese, A. Crocetti, S. et al. Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. Cancers 2020;12:2724. [ DOI:10.3390/cancers12102724] |
